AtriCure, Inc. ATRC recently announced the treatment of the first patient with the AtriClip FLEX-Mini device. The device recently received the FDA 510(k) clearance. The AtriClip FLEX-Mini, the ...

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management (LAAM), today announced that it has ...

AtriCure, Inc. ATRC recently announced receipt of regulatory approval from China’s National Medical Products Administration (NMPA) for its AtriClip Left Atrial Appendage (LAA) Exclusion System. This ...

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has received ...

AtriCure Inc., with a market capitalization of $1.7 billion, reported its first-quarter 2025 earnings, showing stronger-than-expected performance with an adjusted loss per share of $0.14, surpassing ...

Atricure Inc. (NASDAQ: ATRC), the maker of cardiac surgical ablation systems, has received a conditional nod from the Food and Drug Administration (FDA) to evaluate the safety and efficacy of a hybrid ...

> VeriTeQ, a maker of implantable medical devices for identification and radiation dose measurement, has changed its ticker symbol from "DIGAD" to "VTEQ." Item > TriReme Medical in California said ...

Canaccord Genuity analyst William Plovanic has maintained their bullish stance on ATRC stock, giving a Buy rating on July 31. William Plovanic has given his Buy rating due to a combination of factors ...

AtriCure, Inc. (NASDAQ:ATRC) shareholders should be happy to see the share price up 17% in the last quarter. But that doesn't change the fact that the returns over the last three years have been ...

CE Mark brings the increased functionality of the AtriClip PRO2 device to the European market for use in managing the left atrial appendage; product was launched in the U.S. in April 2016 MASON, Ohio.